<DOC>
	<DOCNO>NCT00002139</DOCNO>
	<brief_summary>To compare uptake azithromycin white cell relative plasma concentration HIV-infected patient .</brief_summary>
	<brief_title>Phase I Study Clinical Pharmacology Azithromycin Buffy Coat HIV-Infected Subjects .</brief_title>
	<detailed_description>Patients randomize receive azithromycin orally intravenously , crossover alternate treatment 21-day wash-out period .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral agent , provide regimen stable least 1 month . Patients must : HIV infection . CD4 count &lt; = 200 cells/mm3 . No active opportunistic infection ( pending discussion Pfizer Clinician ) . Prior Medication : Allowed : Prior antiretroviral agent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active intercurrent illness ( pending discussion Pfizer Clinician ) . Allergies macrolide antibiotic . Signs symptom severe illness would preclude treatment . Patients follow prior condition exclude : History clinically significant allergic , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Clinically important change baseline status within 4 week prior study entry . Condition affect drug absorption ( e.g. , ulcer , gastrectomy , HIVassociated enteropathy ) within 4 week prior study entry . Prior Medication : Excluded : Investigational drug include treatment IND drug within 4 week prior study entry . Known drug alcohol dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Bacterial Infections</keyword>
</DOC>